MAM
NBIX icon

Martingale Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Martingale Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.8M Buy
69,799
+28,776
+70% +$4.27M 0.28% 111
2026
Q1 		$5.4M Buy
41,023
+39,347
+2,348% +$5.22M 0.14% 160
2025
Q4 		$238K Buy
+1,676
New +$243K 0.01% 728
2025
Q2 		– Sell
-3,196
Closed -$353K – 832
2025
Q1 		$353K Sell
3,196
-19,659
-86% -$2.49M 0.01% 656
2024
Q4 		$3.12M Sell
22,855
-3,456
-13% -$427K 0.08% 204
2024
Q3 		$3.03M Sell
26,311
-3,400
-11% -$466K 0.07% 222
2024
Q2 		$4.09M Sell
29,711
-1,326
-4% -$182K 0.09% 177
2024
Q1 		$4.28M Buy
31,037
+4,530
+17% +$619K 0.09% 179
2023
Q4 		$3.49M Buy
26,507
+589
+2% +$67.8K 0.07% 185
2023
Q3 		$2.92M Sell
25,918
-1,954
-7% -$206K 0.06% 199
2023
Q2 		$2.63M Buy
27,872
+88
+0.3% +$8.6K 0.05% 218
2023
Q1 		$2.81M Buy
27,784
+6,061
+28% +$631K 0.05% 208
2022
Q4 		$2.59M Buy
+21,723
New +$2.54M 0.05% 212

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Martingale Asset Management's NBIX Position: Q2 2026 in Review

Martingale Asset Management increased its Neurocrine Biosciences (NBIX) stake by 70% in Q2 2026, buying an estimated $4.27M and bringing the position to 69,799 shares worth $11.8M. The position accounts for 0.28% of the portfolio, ranked #111.

Martingale Asset Management first reported a position in NBIX in Q4 2022 and has held it in 13 quarters since. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Martingale Asset Management held 69,799 shares of Neurocrine Biosciences worth $11.8M as of Q2 2026.
  • Martingale Asset Management bought 28,776 Neurocrine Biosciences shares in Q2 2026, an estimated $4.27M.
  • Neurocrine Biosciences made up 0.28% of Martingale Asset Management's portfolio in Q2 2026, its #111 holding.
  • Martingale Asset Management first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 13 quarters since.
  • 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.